In a patient with stress‑related acute respiratory distress, why should beclomethasone (Clenil) not be administered by nebulization?

Beclomethasone (Clenil) should not be nebulized for acute stress‑related respiratory distress because it does not improve short‑term outcomes (morbidity, mortality, or QoL), delays effective bronchodilation, and is not guideline‑recommended for acute management. 1, 2

• Core recommendation

  • Use rapid bronchodilators (nebulized β‑agonist ± ipratropium) and systemic steroids; do not nebulize beclomethasone for the acute event. 2, 1
  • Rationale:
    • Acute respiratory distress/ARDS: systemic corticosteroids are suggested; inhaled/nebulized ICS are not part of evidence‑based acute care and do not impact mortality/morbidity in ARDS. 1
    • Acute asthma/COPD exacerbation: BTS nebulizer guidance endorses nebulized bronchodilators; it explicitly notes lack of RCT evidence for nebulized corticosteroids in adults and recommends specialist review before considering them, not for acute relief. 2
    • The best quality trials in acute asthma show adding high‑dose inhaled beclomethasone to standard IV steroids and bronchodilators does not improve lung function or symptoms in the ED. 3

• Algorithm (acute dyspnea with suspected bronchospasm vs ARDS)

  1. If bronchospasm (wheeze, reduced PEF):
     • Give nebulized salbutamol 5 mg ± ipratropium 500 µg; repeat per response. 2
     • Start systemic corticosteroid (e.g., IV methylprednisolone). Do not add nebulized beclomethasone; it adds time and no benefit. 3
  2. If ARDS pattern (hypoxemia refractory, bilateral infiltrates, non‑cardiogenic):
     • Lung‑protective ventilation, high PEEP strategy, prone positioning; consider systemic corticosteroids per ATS 2024 (conditional). Inhaled/nebulized beclomethasone has no role. 1
  3. Reassess gas exchange and work of breathing; escalate (NIV/IMV, ECMO where indicated). 1

• Nuances and pitfalls

  • Nebulized steroids can cause oropharyngeal deposition/thrush; if steroids are nebulized (e.g., budesonide respules in select cases), rinse mouth and use mouthpiece—still not for acute rescue. 2
  • Infection control: nebulization increases fugitive aerosols; if nebulizing any drug, use appropriate filters and techniques; avoid unnecessary nebulized agents. 4
  • Off‑label reports exist for nebulized corticosteroids (often budesonide) beyond asthma/COPD, but evidence is heterogeneous and not outcome‑driven; do not substitute for systemic steroids in ARDS or for bronchodilators in acute bronchospasm. 5
  • Beclomethasone (Clenil) “for prevention/control,” not rescue; onset is too slow to relieve acute airflow obstruction, risking deterioration while delaying definitive therapy. BTS notes absence of adult RCT evidence for nebulized corticosteroids in acute asthma. 2

• What to do instead (to improve morbidity, mortality, QoL)

  • Acute asthma/COPD: Nebulized β‑agonist ± ipratropium; systemic steroids early. 2
  • Suspected ARDS: Systemic corticosteroids per ATS 2024, lung‑protective ventilation, higher PEEP without recruitment maneuvers, early prone positioning; avoid nebulized ICS. 1

• Contrasts in evidence

  • Pro‑nebulized ICS: historical/physiologic rationale and device deposition reviews; not outcome‑oriented and not specific to acute distress. 6
  • Highest‑quality acute data: no added benefit of inhaled beclomethasone on top of standard ED therapy; modern ARDS guidelines exclude nebulized ICS. 3, 1